NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Annexon, Inc. (ANNX) Stock Analysis

Annexon, Inc. (ANNX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANNX

$3.86

+$0.03 (+0.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANNX with… →

ANNX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.85
Previous Close
$3.83
Day's Range
3.85–4.07
52-Week Range
2.54–7.18
Volume
4.95M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$731.78M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.13
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$206.69M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
189.58M
1-Year Return
+23.32%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
3.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANNX closed at $3.86, +23.32% over 1 year.

Annexon, Inc. (ANNX) has a market capitalization of $731.78M.

In fiscal 2025, ANNX reported revenue of $0.00.

ANNX Stock Return by Calendar Year

Annexon, Inc. (ANNX) return since Jul 2020: what $10,000 became

1 year
$10,000 $12,332
+23.32%
5 years
$10,000 $2,114
−78.86%
Since Jul 2020
$10,000 $2,173
−78.27%

If you had invested $10,000 in Annexon, Inc. (ANNX) at the close on July 24, 2020, the earliest close on record here, it would have been worth $2,173 at the close on October 21, 2026: −78.27% in total, −21.69% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.11%
2025−2.14%
2024+13.00%
2023−12.19%
2022−55.00%
2021−54.10%
2020 (partial year)+40.93%

As of October 21, 2026.

ANNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$206.69M—
2024$0.00−$138.20M—
2023$0.00−$134.24M—
2022$0.00−$141.95M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$216.41M−$206.69M—
2024$0.00—−$154.07M−$138.20M—
2023$0.00—−$143.72M−$134.24M—
2022$0.00—−$145.60M−$141.95M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Annexon, Inc. (ANNX) at $731.78M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 92 employees.

Over the past 52 weeks the price has ranged from $2.54 to $7.18. The most recent close on file for ANNX is $3.86, dated October 21, 2026. That is +$0.03 (+0.78%) against the previous close. The latest close sits 51.97% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $206.69M. Earnings per share on a trailing basis come to −1.13.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.33. Annualized volatility over the trailing 6 years is 86.92%. Over the trailing twelve months the total return is +23.32%. Across 5 years the annualized return works out at −26.71%.

Growth & Income

The record shows no dividend for ANNX.

The strongest complete calendar year on file is 2024 at +13.00%; the weakest is 2022 at −55.00%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −23.11%.

Peer Comparison

Annexon, Inc. (ANNX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Annexon, Inc. ANNX $731.78M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Annexon, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Visit website →